The optimal follow-up strategy for head and neck squamous cell carcinoma (HNSCC) remains uncertain, with inconsistent international guidelines regarding routine radiological surveillance.
To evaluate the association between baseline metastatic tumor volume measured on computed tomography (CT) and survival outcomes in patients with metastatic renal cell carcinoma (mRCC) receiving nivolumab as second line or later line therapy.
The 22nd National Report on Clinical Trials of Medicinal Products published by the Italian Medicines Agency (AIFA) in July 2026 highlights contrasting trends in Italian clinical research.